Combining the Accuracy of FISH with the Ease of IHC
The SPOT-Light® HER2 CISH Kit is FDA approved as an alternative for IHC or FISH methods. The novel chromogenic ISH (CISH) technology allows for a simplified interpretation scheme compared to both IHC and FISH methods. SPOT-Light® HER2 CISH provides gene amplification results. Several studies have demonstrated that gene amplification tests provide superior correlation to Herceptin® response compared to IHC methods.
° Aids in the selection of patients for Herceptin® therapy
° Quantitative in-situ hybridization results
° Highly concordant (95-99%) with other FDA approved HER2 assays
° Improved consistency and higher reimbursement than IHC
° No requirement for expensive fluorescence microscopy equipment
“CISH has all the advantages of FISH, including a built-in internal control to prevent false-negative results and a more objective slide scoring system than IHC to prevent false-positives. And all this comes in a low-cost, fast, easy-to-score format performed in regular ambient conditions with a routine microscope in a fraction of the time that it takes to score FISH.”
- Dr. Jeffrey Ross, Albany Medical College
Click Here to find more about the FDA approved HER2 CISH Kit
To learn about the HER2 CISH certification program, go to:
www.invitrogen.com/her2cishcert
SPOT-Light® is a registered trademark of Invitrogen Corporation. Herceptin® is a registered trademark of Genentech, Inc. PathVysion® is a registered trademark of Abbott Molecular, Inc.
